Conjugation Delivery Technology
ConjuGon is developing a fundamentally new technology to combat the growing epidemic of antibiotic-resistant bacteria. The technology, based on the work of Dr. Marcin Filutowicz, a Professor in the Bacteriology Department of the University of Wisconsin-Madison, uses the naturally-occurring process of conjugation to deliver engineered genes from harmless donor bacteria to targeted, unwanted bacteria. The genes then are expressed in the target and form antibacterial gene products, called Conjucin TM agents, which proceed to kill the unwanted bacteria through multiple and redundant mechanisms.
Because of the novel delivery method and multiple killing mechanisms, the chance of bacteria becoming resistant to this technology is greatly reduced. Also, unlike traditional, small-molecule antibiotics, the Conjucin TM agents are created at the site of action. They will have a tighter binding action and should greatly reduce the side effects that often occur with chemical antibiotics.
ConjuGon's lead Conjugation Delivery product is to treat the infections of wounds.
